A Systems Approach to Clinical Trial Development with Selection Biomarkers
*Robert Sikorski, Medimmune Keywords: The use of biomarkers to select patients for inclusion in, or exclusion from, clinical trials has garnered much interest. Selection biomarkers can serve as powerful tools to increase the clinical benefit of an investigational agent in defined patient populations. I will discuss a ‘systems’ approach that has served to visualize the landscape of selection biomarkers in active phase III oncology trials. Important patterns in biomarker usage are evident that can guide investigations in both solid and hematological malignancies.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC